



ASX RELEASE

15 April 2011

Dear Option holder

2011 Non-renounceable Rights Issue – Option holder participation

Tissue Therapies Limited (**Tissue Therapies**) today announced the:

- placement of 11.50 million ordinary shares to sophisticated and professional investors at \$0.50 each raising approximately \$5.75 million (**Placement**); and
- lodgement of a prospectus for a non-renounceable rights issue of ordinary shares to existing shareholders at \$0.50 each to raise approximately \$9.36 million (**Rights Issue**).

Tissue Therapies intends to raise approximately \$15.10 million through the Placement and Rights Issue.

The Rights Issue is fully underwritten by RBS Morgans Corporate Limited who was also the manager for the Placement].

Terms of the Rights Issue

The Rights Issue entitles eligible Shareholders to subscribe for 1 new share in Tissue Therapies for every 8 existing shares held at 7.00pm (AEST) on 28 April 2011 (**Record Date**), at an issue price of \$0.50 per share (**New Shares**).

Eligible Shareholders are those persons who are registered holders of shares on the Record Date and having a registered address in Australia or New Zealand (**Eligible Shareholders**).

Option holders may only participate in the Rights Issue if the options are exercised prior to the Record Date.

Please contact the share registry should you wish to exercise your options in Tissue Therapies and participate in the Rights Issue.

The share registry contact details are:

Postal Address

Tissue Therapies Limited
C/- Link Market Services Limited
Locked Bag 3415
BRISBANE QLD 4001

Hand Delivery

Tissue Therapies Limited
C/- Link Market Services Limited
Level 15, 324 Queen Street
BRISBANE QLD 4000

Yours sincerely



Steven Mercer
Chief Executive Officer

Further information please contact

Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: 07 3839 9938
Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair, cell culture and other applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by cell biology, tissue engineering and protein engineering experts at the Institute for Health and Biomedical Innovation (IHBI) at the Queensland University of Technology (QUT) for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, cell based therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective treatments for acute and chronic wound healing applications including chronic skin ulcers and burns.

Tissue Therapies is also proceeding with the development of other commercial applications for VitroGro® and other technologies for the treatment of psoriasis, scar prevention and treatment and potential treatments for various cancers including those of the breast, colon and prostate.

VitroGro® also provides a fundamental, transforming technology for completely defined cell culture reagents (ie. containing no purified animal or human proteins) to sustain and enhance the growth of live cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com